In collaboration with Dr. Robert Ballotti and Professor Jean-Paul Ortonne, both hospital dermatologists and researchers at a major French institute, CEBELIA has been involved in some very innovative research to patent a new regulator of melanogenesis and to fight against hyperpigmentation.
Normal skin pigmentation is mainly due to melanin. Melanocytes are skin cells that produce melanin through a process called melanogenesis, and protect the skin from UV rays. Under the effect of UV rays, hormones and enzymes (&MSH, PKA, tyrosinase, etc.) stimulate the production of melanin in healthy skin. These pigments are stored in organelles called melanosomes, and then sent to the upper layers of the epidermis. This phenomenon provides a natural and even tan. Hyperpigmentation may be due either to the abnormal presence of pigments of endogenous or exogenous origin (drugs, etc.) in the skin or to an overproduction or uneven distribution of melanin (exposure to the sun, hormonal disorders, etc. ).
In order to intervene in the process of melanogenesis, we selected PEKALINE, a patented active ingredient, which works on two levels:
It prevents melanin from being produced inside the cells by inhibiting protein kinase (PKA) and keeps pigments from developing (acidic pH).
The results have been proven: Pekaline reduces melanin levels by 40% in healthy cells and by 80% in cells with stimulated tyrosinase activity. Pekaline also reduces existing pigmentation by approximately 50%.
This patented active ingredient plays a particularly prominent role in our CEBELIA Reinforced Depigmenting skincare formula that combines Vitamin C, Vitamin PP and glycolic acid for their spot-reducing synergy.
[LEARN MORE ABOUT CEBELINE: OUR 2ND PATENTED INGREDIENT]